CMB International Global Markets | Equity Research | Company Update

# **Bosideng (3998 HK)**

## From winter clothing to all seasons clothing

We think the guidance raise is a key moment for the company, as the success that Bosdieng has achieved in the sun-protective product series shows that it is capable of generating sales in all seasons (other than just fall and winter). Also, despite our raises in estimates and TP, we still think our numbers are conservative. The company is only trading at 12x FY3/25E P/E and a 7% yield, still fairly attractive in our view.

- FY3/24E guidance raised, driven by both industry and company reasons. During its new product launch event last week, Bosideng raised its FY24E guidance to 30%+ sales growth and even faster NP growth (from 20%+ in Jan 2024), thanks to macro reasons (CNY was later than last year's and favorable weather since Dec 2023) and various company-specific reasons such as: 1) successful category expansion (e.g., sun-protective achieved 300%+ sales growth to around RMB500mn in FY3/24E), 2) impressive new product launches (e.g. Ultralight down apparel had a surge in sales growth of 70%+ to around RMB3.0bn in FY3/24E, much faster than the guidance of 30%+; the 3-in-1 windbreakers were also extremely hotselling) and 3) effective boost in store efficiency through the TOP strategy (top 500 stores contributed about 60% of down apparel sales, top 17% SKUs made up around 70% of sales and 180+ stores registered RMB10mn+ in annual sales per store, etc.).
- Company is still confident on its rapid growth in FY3/25E and we do think that is feasible. Management is still highly confident about its growth in FY3/25E and even in FY3/26E-27E, and we have conservatively estimated 14% sales growth and 17% net profit growth in FY3/25E. We believe the sales growth from sun-protective clothing series could be explosive (FY25E target is at around RMB1.bn, implying 100%+ sales growth; the YTD sales growth is already at 80%+), as: 1) the company will launch a new City Outdoor Series/ 都市轻户外系列 on top of the already hot-selling Scorching Sun series/ 骄阳系列, 2) products will be placed into more stores (to around 1,500+ direct retail stores, from 1,000+ stores last year and will also sell to the distributor stores), 3) more A&P expenses will be spent around these product series. Moreover, sales of the sun-protective clothing will also help acquire more potential customers for down apparel in the up-coming winter. Similarly, we are also confident on the development of Ultralight down apparel (FY25E target is at around RMB4.5bn, implying 30%+ sales growth, from RMB3.0bn+ last year), thanks to expansion of product series and further upgrades in designs and functionality. Moreover, this kind of products can effective extend sales seasons of Bosideng's products from winter to other seasons during the year.

## **Earnings Summary**

(YE 31 Mar)	FY22A	FY23A	FY24E	FY25E	FY26E
Revenue (RMB mn)	16,214	16,774	21,939	25,074	27,739
YoY growth (%)	20.0	3.5	30.8	14.3	10.6
Operating profit (RMB mn)	2,568.8	2,826.4	3,693.2	4,402.1	5,014.4
Net profit (RMB mn)	2,058.8	2,156.4	2,885.4	3,451.8	3,950.8
EPS (Reported) (RMB)	0.18	0.19	0.25	0.30	0.34
YoY growth (%)	20.0	2.9	34.4	17.5	14.5
P/E (x)	19.7	19.2	14.3	12.1	10.6
P/B (x)	3.1	3.1	2.9	2.6	2.4
Yield (%)	3.9	4.1	5.0	5.9	6.8
ROE (%)	17.7	17.4	22.1	24.5	25.9
Net gearing (%)	2.2	25.2	28.4	31.9	34.7

Source: Company data, Bloomberg, CMBIGM estimates



## **BUY (Maintain)**

Target Price	HK\$5.34
(Previous TP	HK\$3.86)
Up/Downside	23.5%
Current Price	HK\$4.32

### **China Consumer Discretionary**

Walter WOO

(852) 3761 8776 walterwoo@cmbi.com.hk

### Stock Data

Mkt Cap (HK\$ mn)	46,718.6
Avg 3 mths t/o (HK\$ mn)	82.7
52w High/Low (HK\$)	4.32/2.89
Total Issued Shares (mn)	10814.5
Source: FactSet	

### **Shareholding Structure**

Mr. Gao De Kang & Family	70.3%
Orient Securities Asset	1.9%
Management	
Source: HKEx	

## Share Performance

	Absolute	Relative
1-mth	5.1%	7.1%
3-mth	25.2%	18.2%
6-mth	29.0%	37.5%
Source: FactSet		

#### **12-mth Price Performance**



#### **Recent Reports:**

Xtep (1368 HK) - Steady recovery shall continue with high yield (19 Apr 24)

Anta (2020 HK) - An inline 1Q24 plus an improving outlook (18 Apr 24)

Li Ning (2331 HK) - Expectations reset with positive initiatives (21 Mar 24)

<u>China Lilang (1234 HK) – Impressive</u> <u>FY24E guidance with decent yield</u> (20 Mar 24)

<u>361 Degrees (1361 HK) – Resilient</u> <u>outlook backed by rising popularity</u> (14 Mar 24)



Maintain BUY and raise TP to HK\$5.34. We revise up FY3/24E-26E net profit by 11%-13% to factor in: 1) a beat in sales due to favorable weather, 2) positive reception of many new products and 3) better-than-expected operating leverage. We do think this guidance raise is a key moment for the company, as the success that Bosdieng has achieved in the sun-protective product series shows that it is capable of generating sales in all seasons (other than just fall and winter). So we maintain BUY and raise its TP to HK\$5.34, based on 15x FY3/25E P/E (raised and rolled over from 14x FY3/24E P/E). It is trading at 12x FY3/25E P/E, still attractive in our view, vs 18%/ 22% sales/ NP CAGRs and a 5-year average of 16x.

## **Earnings revision**

## Figure 1: Earnings revision

		New			Old		Diff (%)			
RMB mn	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	
Revenue	21,939	25,074	27,739	19,432	21,325	22,964	12.9%	17.6%	20.8%	
Gross profit	13,168	15,150	16,872	11,537	12,715	13,763	14.1%	19.2%	22.6%	
EBIT	3,693	4,402	5,014	3,381	3,943	4,404	9.2%	11.6%	13.9%	
Net profit att.	2,874	3,377	3,868	2,599	3,013	3,410	10.6%	12.1%	13.4%	
Diluted EPS (RMB)	0.251	0.295	0.338	0.229	0.266	0.301	9.7%	11.2%	12.5%	
Gross margin	60.0%	60.4%	60.8%	59.4%	59.6%	59.9%	0.7ppt	0.8ppt	0.9ppt	
EBIT margin	16.8%	17.6%	18.1%	17.4%	18.5%	19.2%	-0.6ppt	-0.9ppt	-1.1ppt	
Net profit att. margin	13.1%	13.5%	13.9%	13.4%	14.1%	14.8%	-0.3ppt	-0.7ppt	-0.9ppt	

Source: Company data, CMBIGM estimates

## Figure 2: CMBIGM estimates vs consensus

		CMBIGM			Consensus			Diff (%)	
RMB mn	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	21,939	25,074	27,739	20,046	22,987	26,097	9.4%	9.1%	6.3%
Gross profit	13,168	15,150	16,872	11,990	13,783	15,684	9.8%	9.9%	7.6%
EBIT	3,693	4,402	5,014	3,431	3,987	4,605	7.6%	10.4%	8.9%
Net profit att.	2,874	3,377	3,868	2,684	3,131	3,627	7.1%	7.8%	6.6%
Diluted EPS (RMB)	0.251	0.295	0.338	0.246	0.287	0.332	2.2%	2.8%	2.0%
Gross margin	60.0%	60.4%	60.8%	59.8%	60.0%	60.1%	0.2ppt	0.5ppt	0.7ppt
EBIT margin	16.8%	17.6%	18.1%	17.1%	17.3%	17.6%	-0.3ppt	0.2ppt	0.4ppt
Net profit att. margin	13.1%	13.5%	13.9%	13.4%	13.6%	13.9%	-0.3ppt	-0.2ppt	0ppt

Source: Company data, Bloomberg, CMBIGM estimates



# **Results preview**

Figure 3: Earnings preview - Half Year

Half yearly - (Mar year-end)	1H23	2H23	1H24	2H24E	1H23	2H23	1H24	2H24E
(RMB mn)					ΥοΥ	ΥοΥ	ΥοΥ	ΥοΥ
Revenue	6,180	10,594	7,472	14,468	14%	-2%	21%	37%
COGS	-3,091	-3,707	-3,738	-5,033				
Gross profit	3,089	6,887	3,733	9,435	12%	-1%	21%	37%
GP margin	50.0%	65.0%	50.0%	65.2%				
Other income & gains	105	205	110	197				
S&D expenses	-1,623	-4,502	-2,030	-6,083	1%	-1%	25%	35%
S&D exp / sales	- 26.3%	-42.5%	-27.2%	-42.0%				
Admin expenses	-525	-679	-582	-978	16%	-10%	11%	44%
Admin exp / sales	-8.5%	-6.4%	-7.8%	<b>-6.8%</b>				
Other opex	-3	-10	-0	-43				
Operating profit (EBIT)	1,043	1,901	1,231	2,528	31%	5%	18%	33%
OP margin	16.9%	1 <b>7.9</b> %	16.5%	17.5%				
Other items	-98	-20	0	-66				
Net finance income	69	14	82	116				
Net finance income / sales	1.1%	0.1%	1.1%	0.8%				
Profit after financing costs	1,014	1,895	1,312	2,579				
Associated coms	-7	-15	-12	-32				
Jointly controlled coms	0	0	0	0				
Pre-tax profit	1,007	1,880	1,301	2,547	22%	2%	29%	35%
Тах	-283	-448	-384	-577				
Tax / sales	-4.6%	-4.2%	-5.1%	-4.0%				
Effective tax rate	- 28.1%	-23.8%	-29.6%	-22.7%				
Minority interests	-10	28	-2	13				
Net profit att.	734	1,404	919	1,956	15%	-1%	25%	39%
NP margin	11.9%	13.3%	12.3%	13.5%				

Source: Company data, CMBIS estimates



## Figure 4: Earnings preview - Full Year

Full yearly - (Mar year-end) (RMB mn)	FY23	FY24E	FY25E	FY24E YoY	FY25E YoY
Revenue	16,774	21,939	25,074	31%	14%
COGS	-6,798	-8,771	-9,924		
Gross profit	9,976	13,168	15,150	32%	15%
GP margin	59.5%	60.0%	60.4%		
Other income & gains	310	307	301		
S&D expenses	-6,125	-8,113	-9,194	32%	13%
S&D exp / sales	-36.5%	-37.0%	-36.7%		
Admin expenses	-1,204	-1,560	-1,729	30%	11%
Admin exp / sales	-7.2%	-7.1%	-6.9%		
Other opex	-12	-44	-50		
Operating profit (EBIT)	2,944	3,759	4,477	28%	19%
OP margin	17.6%	17.1%	17.9%		
Other items	-118	-66	-75		
Net finance income	83	198	250		
Net finance income / sales	0.5%	0.9%	1.0%		
Profit after financing costs	2,910	3,891	4,653		
Associated coms	-22	-44	-50		
Jointly controlled coms	0	0	0		
Pre-tax profit	2,887	3,847	4,602	33%	20%
Тах	-731	-962	-1,151		
Tax / sales	-4.4%	-4.4%	-4.6%		
Effective tax rate	-25.3%	-25.0%	-25.0%		
Minority interests	18	11	75		
Net profit att.	2,139	2,874	3,377	34%	17%
NP margin	12.7%	13.1%	13.5%		

Source: Company data, CMBIGM estimates



## Valuation


## Figure 5: Peers' valuation

			12m TP	Price	Up/ Down-	Mkt. Cap	Year	P/E	(x)	Р/В (x)	ROE (%)	3yrs PEG (x)	Yield (%)	YTD perf. (%)
Company	Ticker	Rating	(LC)	(LC)	side	(HK\$mn)	End	FY1E	FY2E	FY1E	FY1E	FY1E	FY1E	FY1E
H-share Apparel														
Bosideng Intl	3998 HK	BUY	5.34	4.32	24%	47,179	Mar-23	14.3	12.1	2.6	19.7	0.7	5.1	23.1
China Lilang	1234 HK	BUY	5.75	4.77	21%	5,712	Dec-23	8.7	7.7	1.2	13.7	0.7	8.3	12.8
Jnby Design	3306 HK	BUY	19.77	13.44	47%	6,972	Jun-23	7.6	6.7	2.6	40.2	0.5	12.2	31.6
Cosmo Lady	2298 HK	NR	n/a	0.23	n/a	508	Dec-23	7.7	5.6	0.2	2.2	0.5	n/a	(5.4)
Mulsanne Group	709 HK	NR	n/a	1.81	n/a	2,921	Dec-23	7.9	7.5	n/a	15.3	1.2	n/a	(31.4)
Giordano	1817 HK	NR	n/a	1.15	n/a	1,093	Dec-23	n/a	n/a	n/a	5.7	0.0	n/a	64.3
Koradior	3709 HK	NR	n/a	12.46	n/a	8,772	Dec-23	8.0	6.9	1.4	19.6	0.6	7.9	(12.1)
							Avg. Med.	9.0 7.9	7.8 7.2	1.6 1.4	16.6 15.3	0.6 0.6	8.4 8.1	11.8 12.8
A-share Apparel														
Ningbo Peacebird	603877 CH	NR	n/a	14.85	n/a	7,613	Dec-23	11.9	10.3	1.3	8.0	0.6	4.5	(13.1)
Joeone Co Ltd	601566 CH	NR	n/a	9.56	n/a	5,944	Dec-22	24.5	15.3	1.3	3.1	(0.1)	2.9	(4.1)
Fujian Septwolves	002029 CH	NR	n/a	5.48	n/a	4,480	Dec-23	14.1	12.5	0.6	4.1	1.9	n/a	(4.4)
Hla Corp Ltd	600398 CH	NR	n/a	9.40	n/a	48,845	Dec-22	13.9	12.2	2.3	19.2	0.8	4.7	26.7
Jiangsu Hongdou	600400 CH	NR	n/a	2.50	n/a	6,220	Dec-22	83.3	62.5	1.9	0.3	1.2	n/a	(10.4)
Dazzle Fashion	603587 CH	NR	n/a	13.34	n/a	6,890	Dec-22	11.6	9.8	1.5	11.6	0.5	5.8	1.8
Anzheng Fashion	603839 CH	NR	n/a	5.08	n/a	2,194	Dec-22	n/a	n/a	n/a	(16.6)	0.0	n/a	(38.8)
Lancy Co Ltd	002612 CH	NR	n/a	15.97	n/a	7,645	Dec-22	30.9	23.1	2.1	6.5	0.2	0.9	(17.0)
Shenzhen Huijie	002763 CH	NR	n/a	7.36	n/a	3,264	Dec-23	n/a	n/a	n/a	9.0	0.0	n/a	(12.5)
Ellassay Fashion	603808 CH	NR	n/a	7.61	n/a	3,039	Dec-22	12.6	8.6	0.9	2.6	0.1	2.0	(17.0)
							Avg.	25.4	19.3	1.5	4.8	0.5	3.5	(8.9)
							Med.	14.0	12.3	1.4	5.3	0.4	3.7	(11.4)
International Appa	arel													
Canada Goose	GOOS US	NR	n/a	11.42	n/a	8,636	Apr-23	18.5	15.4	2.9	11.4	0.0	0.0	(3.6)
Moncler Spa	MONC IM	NR	n/a	65.44	n/a	150,081	Dec-23	27.0	24.1	4.4	20.0	2.6	1.9	17.5
Hugo Boss	BOSS GR	NR	n/a	49.25	n/a	28,936	Dec-23	11.7	9.5	2.0	21.4	0.8	3.1	(27.0)
Next	NXT LN	NR	n/a	8774.0	n/a	108,255	Jan-24	14.3	13.3	5.0	60.0	5.1	2.5	8.1
Hennes & Mauritz	HMB SS	NR	n/a	171.10	n/a	199,910	Nov-23	19.2	17.2	5.1	19.1	0.8	4.1	(3.1)
Industria De Diseno	ITX SM	NR	n/a	43.74	n/a	1,137,692	Jan-24	23.2	21.4	6.5	30.2	2.9	3.5	10.9
Ovs Spa	OVS IM	NR	n/a	2.38	n/a	5,778	Jan-24	8.2	7.8	0.7	5.8	0.4	4.1	6.3
Pvh Corp	PVH US	NR	n/a	106.78	n/a	48,253	Feb-24	9.7	8.4	1.0	13.1	0.8	0.1	(12.6)
Vf Corp	VFC US	NR	n/a	12.83	n/a	39,076	Apr-23	11.8	9.8	1.8	(28.2)	0.2	6.1	(31.8)
Marks & Spencer	MKS LN	NR	n/a	245.80	n/a	48,675	Apr-23	10.6	9.8	1.4	13.9	0.7	1.2	(9.8)
							Avg.	15.4	13.7	3.1	16.7	1.4	2.7	(4.5)
							Med.	13.1	11.5	2.5	16.5	0.8	2.8	(3.4)

Source: Company data, Bloomberg, CMBIGM estimates



## Figure 6: Forward 12M P/E valuation band



Source: Bloomberg, CMBIGM estimates



# **Financial Summary**

INCOME STATEMENT	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Mar (RMB mn)						
Revenue	13,517	16,214	16,774	21,939	25,074	27,739
Cost of goods sold	(5,592)	(6,476)	(6,798)	(8,771)	(9,924)	(10,867)
Gross profit	7,924	9,737	9,976	13,168	15,150	16,872
Operating expenses	(5,903)	(7,442)	(7,459)	(9,782)	(11,049)	(12,191)
Selling expense	(4,807)	(6,171)	(6,125)	(8,113)	(9,194)	(10,181)
Admin expense	(1,026)	(1,203)	(1,204)	(1,560)	(1,729)	(1,872)
Others	(70)	(68)	(130)	(110)	(125)	(139)
Operating profit	2,225	2,569	2,826	3,693	4,402	5,014
Other income	204	274	310	307	301	333
Share of (losses)/profits of associates/JV	0	(14)	(22)	(44)	(50)	(55)
EBITDA	2,789	3,119	3,413	4,187	4,870	5,444
Depreciation	(451)	(437)	(474)	(381)	(355)	(317)
Other amortisation	(113)	(113)	(113)	(113)	(113)	(113)
Interest income	213	316	293	412	464	523
Interest expense	(196)	(199)	(210)	(214)	(214)	(214)
Other income/expense	0	0	0	0	0	0
Pre-tax profit	2,242	2,672	2,887	3,847	4,602	5,268
Income tax	(537)	(613)	(731)	(962)	(1,151)	(1,317)
Minority interest	5	4	(18)	(11)	(75)	(83)
Net profit	1,705	2,059	2,156	2,885	3,452	3,951
BALANCE SHEET	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Mar (RMB mn)						
Current assets	12,877	14,737	14,722	16,886	18,589	20,168
Cash & equivalents	1,771	2,503	3,718	4,400	5,221	6,066
Account receivables	876	1,237	923	1,207	1,380	1,526
Inventories	2,646	2,688	2,689	3,470	3,926	4,299
Prepayment	1,168	1,281	1,355	1,773	2,026	2,241
ST bank deposits	307	306	1,824	1,824	1,824	1,824
Other current assets	6,109	6,722	4,212	4,212	4,212	4,212
Non-current assets	6,080	6,547	6,221	6,347	6,589	6,944
PP&E	1,762	1,758	1,728	2,011	2,415	2,939
Investment in JVs & assos	0	136	236	192	142	2,333
Intangibles	1,572	1,496	1,342	1,229	1,117	1,004
Other non-current assets	2,746	3,157	2,915	2,915	2,915	2,915
Total assets	18,956	21,284	20,943	23,233	25,178	2,313
			·			
Current liabilities	5,442	6,610	6,054	7,337	8,096	8,724
Short-term borrowings	671	934	770	770	770	770
Account payables	2,469	3,283	3,097	3,996	4,522	4,951
Tax payable	520	620	669	669	669	669
Other current liabilities	1,783	1,773	1,517	1,902	2,135	2,334
Non-current liabilities	2,263	2,447	2,284	2,284	2,284	2,284
Long-term borrowings	0	0	0	0	0	0
Other non-current liabilities	2,263	2,447	2,284	2,284	2,284	2,284
Total liabilities	7,706	9,057	8,338	9,622	10,381	11,009
Share capital	1	1	1	1	1	1
	0	0	0	(655)	168	1,109
Retained earnings						
Other reserves	11,068	12,192	12,546	14,197	14,485	14,767
-	11,068 <b>11,069</b>	12,192 <b>12,193</b>	12,546 <b>12,547</b>	14,197 <b>13,543</b>	14,485 <b>14,654</b>	14,767 <b>15,877</b>
Other reserves						



CASH FLOW	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Mar (RMB mn)						
Operating						
Profit before taxation	2,242	2,672	2,887	3,847	4,602	5,268
Depreciation & amortization	564	550	587	494	468	430
Tax paid	(348)	(593)	(738)	(962)	(1,151)	(1,317)
Change in working capital	425	(162)	26	(199)	(123)	(107)
Others	250	202	289	258	264	269
Net cash from operations	3,133	2,670	3,051	3,439	4,061	4,543
Investing	(	()	/>	()	()	( )
Capital expenditure	(437)	(577)	(508)	(665)	(760)	(840)
Acquisition of subsidiaries/ investments	0	0	0	0	0	0
Others	(3,426)	(109)	1,125	0	0	0
Net cash from investing	(3,863)	(686)	617	(665)	(760)	(840)
Financing	(880)	(1,200)	(4 700)	(1.070)	(2,266)	(2 6 4 4)
Dividend paid	(880) 148	(1,309) 360	(1,722)	(1,878) 0	(2,266) 0	(2,644) 0
Net borrowings Proceeds from share issues	0	0	(210) 0	0	0	0
Share repurchases	(135)	(14)	0	0	0	0
Others	(133)	(14)	(561)	0	0	0
Net cash from financing	(1,092)	(1,232)	(2,493)	(1,878)	(2,266)	(2,644)
Net change in cash						
Cash at the beginning of the year	3,639	1,771	2,503	3,718	4,400	5,221
Exchange difference	(46)	(21)	41	0	0	0
Others	(1,822)	752	1,174	682	821	844
Cash at the end of the year	1,771	2,503	3,718	4,400	5,221	6,066
GROWTH	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Mar						
Revenue	10.9%	20.0%	3.5%	30.8%	14.3%	10.6%
Gross profit	18.1%	22.9%	2.5%	32.0%	15.0%	11.4%
Operating profit	39.2%	15.5%	10.0%	30.7%	19.2%	13.9%
EBITDA	39.5%	11.9%	9.4%	22.7%	16.3%	11.8%
Net profit	42.6%	20.8%	4.7%	33.8%	19.6%	14.5%
PROFITABILITY	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Mar						
Gross profit margin	58.6%	60.1%	59.5%	60.0%	60.4%	60.8%
Operating margin	16.5%	15.8%	16.8%	16.8%	17.6%	18.1%
EBITDA margin	20.6%	19.2%	20.3%	19.1%	19.4%	19.6%
Return on equity (ROE)	16.0%	17.7%	17.4%	22.1%	24.5%	25.9%
GEARING/LIQUIDITY/ACTIVITIES	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Mar	(2.2)					
Net debt to equity (x)	(0.0)	0.0	0.3	0.3	0.3	0.3
Current ratio (x)	2.4	2.2	2.4	2.3	2.3	2.3
Receivable turnover days	23.7	27.8	20.1	20.1	20.1	20.1
Inventory turnover days	172.7	151.5	144.4	144.4	144.4	144.4
Payable turnover days	161.1	185.0	166.3	166.3	166.3	166.3
VALUATION YE 31 Mar	2021A	2022A	2023A	2024E	2025E	2026E
P/E	24.1	19.7	19.2	14.3	12.1	10.6
P/E (diluted)		19.7			12.1	
P/B	24.1 3.5	19.7 3.1	19.2 3.1	14.3 2.9	12.1 2.6	10.6 2.4
P/CFPS	3.5 14.4	17.0	15.0	13.3	2.0 11.2	2.4 10.1
Div yield (%)	2.8	3.9	4.1	5.0	5.9	6.8
EV	46,340.2	45,992.2	43,553.7	42,872.0	42,050.7	41,206.2
EV/Sales	3.4	2.8	2.6	2.0	1.7	1.5
EV/EBITDA	16.6	14.7	12.8	10.2	8.6	7.6
	10.0		12.0	10.2	0.0	1.0

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.



# **Disclosures & Disclaimers**

## **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings BUY HOLD SELL NOT RATED	: Stock with potential return of over 15% over next 12 months : Stock with potential return of +15% to -10% over next 12 months : Stock with potential loss of over 10% over next 12 months : Stock is not rated by CMBIGM
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

### CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800 CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

### **Important Disclosures**

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

#### For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

#### For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investors that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report should do so only through a U.S.-registered broker-dealer.

#### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.